scholarly journals Barriers towards HPV Vaccinations for Boys and Young Men: A Narrative Review

Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1644
Author(s):  
Maria Grandahl ◽  
Tryggve Nevéus
Keyword(s):  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Healthcare Providers ◽  
Young Men ◽  
Final Analysis ◽  
Narrative Review ◽  
Vaccine Hesitancy ◽  
Attitudes And Beliefs ◽  
National Immunization ◽  
Sex With Men

Background: HPV vaccination of both girls and boys can protect against infection and eliminate the risk for HPV-associated cancer. Due to a common misconception that the virus only poses risks to women, vaccine coverage is suboptimal among men in many countries. It is urgent to identify barriers to vaccination of boys and men. Methods: We conducted a narrative review of publications examining attitudes and beliefs regarding HPV vaccination for boys and young men. The electronic databases searched were PubMed, PsychInfo and Scopus (December 2020; last update July 2021). A total of 103 original articles were included in the final analysis. Results: The central barriers against vaccination of boys and men are: (1) lack of knowledge, (2) vaccine hesitancy in general, (3) lack of recommendation from and/or discussions with healthcare providers, (4) cost and logistics, and (5) the idea that HPV vaccination may promote promiscuity. Men who have sex with men and families belonging to ethnic minorities express a need for information tailored to their situation. Conclusions: Boys should be included in national immunization programs and men should also be offered catch-up vaccinations. Future studies should focus on addressing vaccine hesitancy and developing interventions to promote pan-gender HPV vaccination.

scholarly journals Mobile App Strategy to Facilitate Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men: Pilot Intervention Study (Preprint)

2020 ◽  
Author(s):  
Holly B Fontenot ◽  
Bradley Patrick White ◽  
Joshua G Rosenberger ◽  
Hailee Lacasse ◽  
Chokdee Rutirasiri ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Pilot Study ◽  
Design Thinking ◽  
Online Dating ◽  
Care Delivery ◽  
Hpv Vaccination ◽  
Young Men ◽  
Mobile App ◽  
Young Msm ◽  
Sex With Men

BACKGROUND Mobile app-based interventions have been identified as potential facilitators for vaccination among young men who have sex with men (MSM). OBJECTIVE This pilot study aimed to test the feasibility of a theoretically informed mobile health (mHealth) tool designed to reduce health disparities and facilitate human papillomavirus (HPV) vaccination among a sample of young MSM. METHODS The development of the mHealth tool was guided by previous research, implementation intention theory, and design thinking. We recruited MSM aged 18-26 years through a popular online dating app and linked participants to our mHealth tool, which provided HPV vaccine information and fostered access to care. RESULTS A total of 42 young MSM participated in this pilot study in Boston, Massachusetts. Participants reported variable HPV knowledge (ie, high knowledge of HPV risk factors and low knowledge of HPV-related cancer risks for men) and positive vaccine beliefs and attitudes. Of those who were either unvaccinated, not up to date, or did not report vaccine status, 23% (8/35) utilized the mHealth tool to obtain HPV vaccination. Participants primarily utilized the tool’s (1) educational components and (2) capabilities facilitating concrete vaccine action plans. CONCLUSIONS We recruited an underserved at-risk population of youth via an online dating app for our mHealth intervention that resulted in in-person health care delivery. This study was limited by enrollment challenges, including low willingness to download the mHealth tool to mobile devices.

Young Men's Disclosure of Same Sex Behaviors to Healthcare Providers and the Impact on Health: Results from a US National Sample of Young Men Who Have Sex with Men

2017 ◽  
Vol 31 (8) ◽  
pp. 342-347 ◽  
Author(s):  
Nathan W. Stupiansky ◽  
Adrian Liau ◽  
Joshua Rosenberger ◽  
Susan L. Rosenthal ◽  
Wanzhu Tu ◽  
...  
Keyword(s):  
Healthcare Providers ◽  
Young Men ◽  
National Sample ◽  
Same Sex ◽  
Sex Behaviors ◽  
Sex With Men ◽  
The Impact

scholarly journals Who Will Benefit From Expanding HPV Vaccination Programs to Boys?

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Venetia Qendri ◽  
Johannes A Bogaards ◽  
Johannes Berkhof
Keyword(s):  
Cancer Prevention ◽  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Cervical Cancer Prevention ◽  
Heterosexual Men ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Programs ◽  
Herd Protection ◽  
Life Years ◽  
Sex With Men

Abstract Indications for human papillomavirus vaccination programs are expanding to boys. However, the rationale behind their inclusion is often not clear. Using a Bayesian synthesis framework and assuming equal vaccine coverage in both sexes, we assessed how the incremental number of cancer cases prevented and life-years gained from boys’ vaccination are distributed between women, heterosexual men, and men who have sex with men (MSM). Below 60% coverage, at least 50% of the gains from boys’ vaccination was attributable to cervical cancer prevention, whereas at 80% coverage, 50% of the gains was attributable to women, 15% to heterosexual men, and 35% to MSM. Above 90% coverage, 85–100% of the gains from boys’ vaccination was attributable to anal and oropharyngeal cancer prevention, mainly in MSM. Sex-neutral vaccination can be advocated on grounds of bolstering herd protection to women and directly protecting men, particularly MSM, with the clinical significance of either argument determined by the coverage.

scholarly journals Low vaccination coverage for human papillomavirus disease among young men who have sex with men, France, 2019

2021 ◽  
Vol 26 (50) ◽  
Author(s):  
Giuseppina Ortu ◽  
Anne-Sophie Barret ◽  
Kostas Danis ◽  
Lucie Duchesne ◽  
Daniel Levy-Bruhl ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccination Coverage ◽  
Rural Areas ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Cross Sectional ◽  
Vaccination Uptake ◽  
Sex With Men

Background In France, human papillomavirus (HPV) vaccination has been recommended in 2016 for men who have sex with men (MSM) up to age 26 years. Aim We aimed to estimate HPV vaccine coverage in 18–28 year-old MSM and identify uptake determinants. Methods We collected data on socio-demographic characteristics, sexual behaviour, sexually transmitted diseases (STI) screening and vaccination uptake using a voluntary cross-sectional online survey conducted in 2019 targeting MSM. We calculated coverage of at least one dose of HPV vaccine and prevalence ratios (PR) of determinants with 95% confidence intervals (CI) using Poisson regression. Results Of 9,469 respondents (age range: 18–28 years), 15% (95% CI: 14–16) reported being vaccinated for HPV. Coverage was significantly higher among MSM < 24 years (PR: 1.25; 95% CI: 1.13–1.39), with education level below university degree (PR: 1.12; 95% CI: 1.08–1.32), living in rural areas (PR: 1.21; 95% CI: 1.08–1.36), attending sex parties (PR: 1.12; 95% CI: 1.03–1.33), using HIV-related biomedical prevention methods (PR: 1.31; 95% CI: 1.12–1.54), with STI diagnosis (PR: 1.22; 95% CI: 1.08–1.38) and with hepatitis A or B vaccination (PR: 4.56; 95% CI: 3.63–5.81 vs PR: 3.35; 95% CI: 2.53–4.44). Conclusions The HPV vaccination uptake among MSM in France was not satisfactory. It was higher among MSM benefitting from other vaccinations and biomedical preventive methods against HIV, suggesting a synergistic effect of the national preventive sexual health recommendations for MSM. Further efforts to improve HPV vaccination coverage targeting MSM are warranted.

scholarly journals Cervical Cancer Protection in Japan: Where Are We?

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1263
Author(s):  
Asami Yagi ◽  
Yutaka Ueda ◽  
Mamoru Kakuda ◽  
Satoshi Nakagawa ◽  
Kosuke Hiramatsu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Significant Risk ◽  
Vaccine Hesitancy ◽  
Lead Agency ◽  
Medical Institutions ◽  
National Immunization ◽  
Life Saving ◽  
Japanese Mothers

In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged 13–16 commenced in 2010. By early 2013, vaccination had become a widely accepted national immunization program. However, in June of 2013, the Ministry of Health, Labor, and Welfare (MHLW), the government’s lead agency, suspended its recommendation for vaccination in response to reports of adverse vaccine events. The rate of HPV vaccination quickly dropped from 70% to almost zero, where it has lingered for eight years. In 2020, a new 9-valent HPV vaccine was licensed in Japan. The momentum seemed to be building for the resumption of HPV vaccinations, yet Japanese mothers remain widely hesitant about vaccinating their daughters, despite the well-proven safety and efficacy of the HPV vaccines. The Japanese government and our educational and medical institutions must work harder as a team to inform our parents and their children about the life-saving benefits of the HPV vaccine, and at the same time, we must respond to all their concerns and questions. The vaccine hesitancy of unvaccinated women born in 2000 and thereafter is a natural consequence of the suspension of the government‘s recommendation. We must also take every possible measure to reduce the significant risk for cervical cancer these women have.

scholarly journals Trial design and protocol of randomized controlled trial comparing the efficacy of oral mefenamic acid, paracetamol and placebo for analgesic prophylaxis in childhood vaccination (MAP VaC trial)

2021 ◽  
Vol 8 (3) ◽  
pp. 218
Author(s):  
Rachna Pasi ◽  
Thirunavukkarasu Arun Babu ◽  
Vinoth Kumar Kallidoss
Keyword(s):  
Randomized Controlled Trial ◽  
Mefenamic Acid ◽  
Vaccine Coverage ◽  
Controlled Trial ◽  
Childhood Vaccination ◽  
Vaccine Hesitancy ◽  
Immunization Schedule ◽  
Vaccine Administration ◽  
Randomized Controlled ◽  
National Immunization

<p class="abstract"><strong>Background:</strong> Needle related pain has been one of the most important concerns for parents of children receiving vaccination. Non-steroidal anti-inflammatory drugs (NSAIDs) like paracetamol and mefenamic acid have been commonly used as analgesics in pediatric population. However, prophylactic administration of these drugs for analgesia during vaccination has not been studied. The main objective of this study is to compare the efficacy of prophylactic paracetamol, mefenamic acid and placebo on needle pain associated with vaccination.</p><p class="abstract"><strong>Methods:</strong> This is a three-arm parallel, triple blind, randomized controlled trial. Children aged 6 weeks to 7 years who need immunization as per national immunization schedule and reporting to pediatric outpatient department (OPD) at tertiary level hospital, AIIMS Mangalagiri, Andhra Pradesh, will be included. All participants will be randomly allotted to any of the three groups by computer based block randomization. Each participant will be given any one of the three drugs as per their allocation. Vaccination will be done as per national immunization schedule after 30 minutes of drug administration. Face, legs, activity, cry, consolability (FLACC) scoring will be done immediately after vaccine administration and repeated at 15 minutes and 30 minutes. All personnel involved in randomization, drug and vaccine administration, FLACC scoring and statistical analysis will be blinded along with parents and children enrolled in the study.</p><p class="abstract"><strong>Conclusions: </strong>If this intervention study shows evidence of a difference between drug and placebo signifying reduction in vaccine related pain with these drugs, this will have a huge impact on National Immunization programme by improving compliance, vaccine coverage and by reducing vaccine hesitancy.</p><p class="abstract"><strong>Trial registration:</strong> Clinical trials registration number is CTRI/2021/01/030239.</p>

scholarly journals Perspectives and preferences for a mobile health tool designed to facilitate HPV vaccination among young men who have sex with men

2019 ◽  
Vol 15 (7-8) ◽  
pp. 1815-1823 ◽  
Author(s):  
Holly B. Fontenot ◽  
Joshua G. Rosenberger ◽  
Katelyn T. McNair ◽  
Kenneth H. Mayer ◽  
Gregory Zimet
Keyword(s):  
Mobile Health ◽  
Hpv Vaccination ◽  
Young Men ◽  
Sex With Men

Increasing HPV vaccination and eliminating barriers: Recommendations from young men who have sex with men

Vaccine ◽  
2016 ◽  
Vol 34 (50) ◽  
pp. 6209-6216 ◽  
Author(s):  
Holly B. Fontenot ◽  
Heidi C. Fantasia ◽  
Ralph Vetters ◽  
Gregory D. Zimet
Keyword(s):  
Hpv Vaccination ◽  
Young Men ◽  
Sex With Men

scholarly journals Impact of a Gender-Neutral HPV Vaccination Program in Men Who Have Sex with Men (MSM)

2021 ◽  
Vol 18 (3) ◽  
pp. 963
Author(s):  
Javier Díez-Domingo ◽  
Víctor Sánchez-Alonso ◽  
Rafael-J. Villanueva ◽  
Luis Acedo ◽  
José Tuells
Keyword(s):  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
Hpv Infection ◽  
Vaccination Program ◽  
Force Of Infection ◽  
Long Term Effect ◽  
Gender Neutral ◽  
Sex With Men ◽  
The Impact

A major challenge in human papillomavirus (HPV) vaccine programs is the universal gender-neutral recommendation, as well as estimation of its long-term effect. The objective of this study is to predict the added benefit of male vaccination, especially in men who have sex with men (MSM), and to analyze the impact of the program on society. We propose a mathematical model of the HPV infection based on a network paradigm. Data from Spain allowed constructing the sexual network. HPV force of infection was taken from literature. Different scenarios using variable vaccine coverage in both males and females were studied. Strong herd immunity is shown in the heterosexual population, with an important decrease of HPV 6/11 infections both in men and in unvaccinated women with an only-women vaccination at 14 years of age. No impact of this program occurred in the infection incidence in MSM. This group would only benefit from a vaccination program that includes males. However, the impact at short term would be lower than in heterosexual men. The protection of MSM can only be achieved by direct vaccination of males. This may have important consequences for public health.

Sign in / Sign up

Export Citation Format

Share Document